The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...

Black Diamond Therapeutics, Inc. BDTX offers a high-leverage oncology setup built around one primary value driver: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor ...

Zongertinib provided substantial clinical benefit for patients with advanced or metastatic HER2-mutant advanced non-small cell lung cancer, surpassing the historical standard of care efficacy for this ...

16.0 months median progression-free survival (mPFS) with firmonertinib indicates strong efficacy in first-line patients with EGFR PACC mutant non-small cell lung cancer (NSCLC). Robust central nervous ...

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

ArriVent BioPharma is hosting a virtual investor event to discuss the firmonertinib clinical program, highlighting their commitment to transparency and engagement with stakeholders. Firmonertinib has ...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R ...

All study participants simultaneously underwent NGS using three sample types: (1) BWF, (2) plasma, and (3) tumor tissue collected during bronchoscopy. The full patient set (FPS) included all enrolled ...

A window of opportunity study for preoperative brigatinib in resectable anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC): WILDERNESS trial. This is an ASCO Meeting Abstract ...